Dark Circles and Under-Eye Discolouration Treatment in Northern Cyprus

A 5–10 minute clinical assessment during your consultation distinguishes between the five mechanisms:

• Skin stretch test: The under-eye skin is gently stretched sideways with a finger. If the discolouration disappears → vascular (vessel) origin. If it remains unchanged → pigment origin. If it reveals a deepening hollow → tear trough.
• Wood's lamp UV examination: Under UV light, pigment-related discolouration intensifies, while vascular discolouration fades. A rapid way to differentiate.
• Head position test: When the head is tilted back and the light source changes, if the shadow shifts → tear trough / volume loss. If the shadow is fixed → pigment or vascular.
• Allergy history: Seasonal allergic rhinitis, facial oedema, frequent eye itching → an oedema-related component is likely.
• 3D skin analysis: UV, cross-polarised and white-light imaging shows pigment, vascular and surface-texture layers separately. Objective data strengthens treatment planning.

After these five steps, we communicate openly with every patient: "Your under-eye discolouration is approximately 60% pigment, 30% vascular and 10% structural hollowing — here is how we plan to treat it accordingly." A treatment locked onto a single mechanism (for example, filler for everyone) is the primary source of dissatisfaction.

In under-eye treatment, every cause has its own tool. Choosing the wrong tool wastes both time and money:

In practice, most patients receive a combination approach. For example: mixed pigment and vascular type → 4 sessions of carboxytherapy + concurrent topical depigmentant + a light peel at three months. Mixed tear trough and pigment → filler first (to resolve the light shadow), then pigment protocol at six months.

What we do not do: Filler for pigment-driven discolouration — it does not help, and can occasionally cause a bulge resembling a herniation. Pigment laser for tear trough — the laser cannot address an anatomical deficit. Hydroquinone for vascular discolouration — it thins the skin, making the vessels even more visible.

At Nis Clinic, the treatment sequence is shared with the patient in writing at consultation; prioritisation is based on the patient's budget, beginning with the most prominent mechanism.

Carboxytherapy is the subcutaneous injection of medical-grade CO₂ through a fine needle. The CO₂ introduced into the tissue creates a local simulated hypoxia signal; when tissues sense "low oxygen", the Bohr effect mechanism triggers vasodilation and increased oxygen release. In the under-eye area, this translates into the following practical outcomes: microcirculation improves in the thin skin, congested veins open, lymphatic drainage increases, and fibroblast stimulation initiates collagen synthesis. With 4–6 sessions, patients with vascular discolouration typically see a meaningful improvement.

Treatment flow:

• Topical anaesthetic cream is optional (15–20 min); the minimal trauma of a 30G needle is tolerable for most patients without it.
• Medical carbon dioxide is delivered via a calibrated device at a flow rate of 20–40 ml per minute, through 4–6 entry points into the under-eye subcutaneous tissue.
• Each session lasts 10–15 minutes. A mild tingling and a faint bubbling sensation beneath the skin are normal.
• Sessions are spaced one week apart; a standard course involves 4–6 sessions.

Recovery: Very slight pinpoint redness at injection sites for 2–4 hours; make-up can be applied the same day; no social downtime. Published literature indicates a 40–60% improvement in vasculature-based discolouration.

Contraindications: Pregnancy, active infection, uncontrolled diabetes, severe anaemia, and certain cardiac arrhythmias (uncommon). Treatment is postponed during a cold or conjunctivitis flare.

Mesotherapy for the under-eye area involves the subcutaneous micro-depot injection of a brightening, hydrating and microcirculation-supporting active ingredient cocktail through a fine needle. The cocktail typically used for the under-eye region includes:

• Hyaluronic acid (low molecular weight — for hydration, not volumisation),
• Vitamins (B-complex, vitamin C — brightening, antioxidant),
• Amino acids (arginine, glutathione — brightening, biostimulant),
• Brightening agents such as kaempferol and niacinamide (in some proprietary cocktails),
• Peptides (e.g. tripeptide-5 for circulation support).

Application: Topical anaesthetic cream 15–20 min + 8–12 micro-point injections into the under-eye area using a 30G/32G needle. Each session takes 15–20 minutes. Sessions are spaced 2–3 weeks apart; the initial course is 4–6 sessions, followed by maintenance every 3–4 months.

Where it is effective: Meaningful improvement in vascular and mixed discolouration; not sufficient alone for pure pigment discolouration, though it adds benefit when combined with a topical depigmentant regimen. Improved skin quality (hydration, radiance, reduced fine lines) is a secondary benefit.

Contraindications: Active infection, pregnancy, known allergy to cocktail ingredients. Patients on anticoagulants have a higher bruising risk (though it is not a contraindication).

Tear trough filler is the correction of the anatomical hollow beneath the eye (the light shadow) using hyaluronic acid. It does not help pigment or vascular discolouration — it is indicated only where an anatomical hollow is present. When this clear boundary is crossed ("let's use filler to cover the darkness"), dissatisfaction and sometimes an aesthetic problem (including the Tyndall effect — a bluish discolouration visible through the skin) can arise.

The right candidate: A patient in whom the skin stretch test reveals a deep shadow hollow, with a visible depression between the bony orbital rim and the lower-lid fat pad, whose skin is thin but not excessively lax. Typical patient age range: 25–55.

Application: First, the area is confirmed to be suitable for filler. Topical anaesthesia for 15 minutes. A long, flexible cannula (not a needle — lower risk of vascular complications) is advanced along the bony orbital rim. A low-hydrophilic, lightly cross-linked hyaluronic acid product is preferred (such as Restylane Refyne, Teosyal Redensity II or Belotero Balance); aggressive fillers (large molecule, high hydrophilicity) are not appropriate for the under-eye area and can cause swelling and a bluish tint. Injection volume: 0.3–0.8 ml per side, conservative.

Recovery: Mild swelling for 24–48 hours; occasional bruising. The product settles fully within two weeks; a clinic review takes place at week two. Duration: 9–15 months.

What not to expect: Filler does not erase dark circles entirely; it removes the light shadow, but the thin skin texture and underlying vessel visibility may persist. A combination approach (filler + carboxytherapy + topical) is the most frequently effective plan.

Complications and reversal: Hyaluronic acid filler is reversible (with hyaluronidase enzyme); in the event of a serious Tyndall effect or vascular complication, enzyme application is held ready at the clinic. Keeping this safety net in the clinic is a clinical requirement.

Laser and peeling options exist for under-eye pigmentation, but this area demands particular caution — the eye globe is close, the skin is very thin, and the risk of post-inflammatory hyperpigmentation (PIH) is elevated.

• Q-switched Nd:YAG laser: Selectively breaks down dark pigment targets. Use in the under-eye area is performed with a protective metal eye shield (with the eye globe shielded). Sessions are spaced 4–6 weeks apart; a course of 4–6 sessions. First choice only for pigment-dominant discolouration and Fitzpatrick skin types I–III. In Fitzpatrick types IV–VI, PIH risk is higher; the pre-treatment and post-treatment protocol must be rigorously followed.
• Fractional laser (1550 nm, erbium YAG): For both tissue renewal and superficial pigment. Rarely applied to the under-eye area; indicated when significant skin rejuvenation is required.
• Chemical peel — mandelic or lactic, superficial: Mild agents are preferred for the under-eye area. Glycolic 30% or TCA cannot be applied to the under-eye — the TCA reaction on such thin skin can be unpredictable. Mandelic 40% or lactic 30% in a series achieves a moderate effect on pigment.

Pigment-targeted laser and peeling are never a standalone first-line treatment. A topical protocol (hydroquinone 2–4%, tranexamic acid, retinoid, vitamin C, consistent mineral SPF) is applied first for 8–12 weeks. We expect a 40–50% improvement during this phase; laser or peeling is then considered for the residual discolouration. This sequence reduces the risk of PIH and worsening.

In under-eye treatment, the most underestimated yet highest-impact element is home skincare. Everything done at the clinic becomes lasting and progressive with a sound home routine — and temporary without one.

Core discipline (recommended for every patient):

• Mineral SPF 50+ daily — not for holidays, but as a routine. UV is the primary trigger for pigmentation. In Northern Cyprus, it should be applied between 08:00 and 17:00 whether or not you go outdoors.
• Retinoid (tretinoin, adapalene) — evening application. Start with a low concentration (0.025% tretinoin or adapalene 0.1%) for the under-eye area; build tolerance gradually. Skin transformation becomes visible at 3–6 months. Contraindicated during pregnancy and breastfeeding.
• Vitamin C serum — morning, before SPF. Antioxidant and brightening. A 10–15% concentration is safe for the under-eye area.
• Caffeine eye cream — mild vascular support. Morning application supports oedema reduction and microcirculation. Not a lasting fix, but a useful complement.
• Adequate sleep (7–9 hours) and hydration. Controls oedema; a noticeable difference can be seen within the first two weeks from this alone.
• Low-salt diet + antihistamine discipline (for allergy sufferers). Reducing oedema reduces shadow.

Targeted agents (recommended at consultation):

• Hydroquinone 2–4% (for pigment-dominant type, prescription only): used in 8–12 week courses with three-month breaks. Provides active melanogenesis inhibition. Continuous use is not advised.
• Topical tranexamic acid 2–5%: An alternative or complement to hydroquinone; reduces both the vascular and pigment component simultaneously.
• Niacinamide 5% and azelaic acid 10–20%: Safe, calming brightening agents that can also be used during pregnancy.

Each patient receives a personalised written home skincare plan at consultation, specifying which product to use in the morning, which in the evening, how often, and when to take a break. Patients who follow the routine consistently require fewer clinic sessions.

• Any patient aged 18 or over with an active concern.
• Darker skin tones (Fitzpatrick IV–VI): PIH hyperpigmentation is the most common cause of under-eye discolouration in this group; outcomes are meaningful with the correct protocol. However, selection is conservative — carboxytherapy, mesotherapy, topical protocols and gentle fractional options are preferred over aggressive laser and peeling.
• Hormonal pigmentation (melasma-related under-eye discolouration): Pigment management uses topical treatment and lifestyle measures (waiting for stabilisation after pregnancy).
• Allergy- or oedema-related discolouration: A combination of allergy management, carboxytherapy drainage and topical support.
• Patients aged 25–45 presenting with a tired appearance: Mixed vascular and early volume loss. Carboxytherapy plus conservative filler.
• Patients aged 50+: Age-related tear trough, tissue volume loss and pigmentation often combine. Filler + mesotherapy + topical regimen + blepharoplasty assessment where indicated.

• Pregnancy and breastfeeding: Retinoids, hydroquinone, laser, mesotherapy and filler are contraindicated during this period. Only gentle hydration, mineral SPF, caffeine eye cream and (after delivery) a mild mesotherapy cocktail are recommended. A standard assessment takes place 3–6 months after delivery.
• Active eye infection, conjunctivitis, blepharitis or dry eye syndrome flare: Treatment is postponed; planning takes place after an ophthalmology review.
• Uncontrolled diabetes, active autoimmune disease, active cancer treatment or prior radiotherapy to the area — specialist assessment required.
• Keloid or hypertrophic scarring tendency: Micro-needling applications are conservative.
• Anticoagulant therapy: Increases bruising risk; the decision to pause anticoagulants before mesotherapy or filler is made in consultation with the treating physician.
• Contact lenses, recent LASIK or other eye surgery: Ophthalmology clearance is required first.
• Patients expecting to be 'rid of dark circles in a single session': Dissatisfaction is inevitable if expectations are not brought to a realistic level. The process and timelines are discussed openly at consultation.

Patients considering surgical options: In patients with advanced age, combined tear trough plus lower-lid laxity plus hypertrophic fat pads, medical aesthetics may be insufficient. In this group, blepharoplasty (eyelid surgery) is discussed. The decision is made together with the patient.

• Five-mechanism clinical assessment: Skin stretch test, Wood's lamp examination, optional 3D skin analysis, allergy and lifestyle review, skin quality evaluation. This 10–15 minute step accounts for half the success of the treatment.
• Differentiated record in the patient file: Cause analysis recorded as "pigment X%, vascular Y%, hollow Z%"; the treatment sequence follows from this breakdown.
• Plastic surgery specialist oversight: Op. Dr. İbrahim Meyzin has thorough knowledge of facial anatomy, fat pad configuration, vascular mapping and surgical revision options — which means the boundary between medical and surgical intervention is defined for each individual patient.

• Tear trough filler product selection is critical: At Nis Clinic, only hyaluronic acid products specifically suited to the under-eye area are used (low hydrophilicity, flexible cross-link, fine-line products). High-hydrophilicity products (such as Juvederm Voluma or Restylane Lyft, which are designed for cheek volumisation) can cause swelling and the Tyndall effect in the under-eye region.
• Hyaluronidase on site: In the event of a complication, hyaluronidase enzyme to dissolve hyaluronic acid filler is held at the clinic; we are prepared for an emergency scenario.
• Medical CO₂ carboxytherapy device: CE-marked clinical device with calibrated flow control.
• Prescription topical protocol products: Prescription-strength agents such as hydroquinone and tranexamic acid are planned under medical supervision — clinical-grade formulations, not over-the-counter "brightening creams".

The greatest source of dissatisfaction we hear from under-eye patients stems from unrealistic expectations. Our consistent position:

• We do not promise that any treatment will erase discolouration completely. A realistic range: 40–60% improvement in pigment-dominant types; 40–60% in vascular types; 70–85% shadow reduction following appropriate tear trough filler.
• We share the time window clearly. Topical regimen: 8–12 weeks. Carboxytherapy: 4–6 sessions (4–6 weeks). Mesotherapy: 4–6 sessions (8–12 weeks). Tear trough filler: stabilisation at two weeks.
• We explain that treatment requires ongoing commitment. If UV exposure continues or home skincare is neglected, results will not last. Maintenance is part of a lifestyle, not a one-off event.
• Genetic pigment cannot be fully erased. In patients of Southern Mediterranean, Middle Eastern or South Asian heritage, periorbital hyperpigmentation is a baseline characteristic — we can improve it, but setting a goal of "the clearest version of your own skin" is healthier than expecting a pale skin tone.

This honesty sometimes directs a patient towards a clinic offering rosier promises — but trust is built this way in the long term. The majority of our patients return for annual maintenance sessions.